The University of Southampton
University of Southampton Institutional Repository

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

Record type: Article

RNA interference (RNAi) is a natural mechanism regulating protein expression that is mediated by small interfering RNAs (siRNA). Harnessing RNAi has potential to treat human disease; however, clinical evidence for the effectiveness of this therapeutic approach is lacking. ALN-RSV01 is an siRNA directed against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein and has substantial antiviral activity in a murine model of RSV infection. We tested the antiviral activity of ALN-RSV01 in adults experimentally infected with wild-type RSV. Eighty-eight healthy subjects were enrolled into a randomized, double-blind, placebo-controlled trial. A nasal spray of ALN-RSV01 or saline placebo was administered daily for 2 days before and for 3 days after RSV inoculation. RSV was measured serially in nasal washes using several different viral assays. Intranasal ALN-RSV01 was well tolerated, exhibiting a safety profile similar to saline placebo. The proportion of culture-defined RSV infections was 71.4 and 44.2% in placebo and ALN-RSV01 recipients, respectively (P = 0.009), representing a 38% decrease in the number of infected and a 95% increase in the number of uninfected subjects. The acquisition of infection over time was significantly lower in ALN-RSV01 recipients (P = 0.007 and P = 0.03, viral culture and PCR, respectively). Multiple logistic regression analysis showed that the ALN-RSV01 antiviral effect was independent of other factors, including preexisting RSV antibody and intranasal proinflammatory cytokine concentrations. ALN-RSV01 has significant antiviral activity against human RSV infection, thus establishing a unique proof-of-concept for an RNAi therapeutic in humans and providing the basis for further evaluation in naturally infected children and adults.

Full text not available from this repository.

Citation

DeVincenzo, John, Lambkin-Williams, Robert, Wilkinson, Tom M.A., Cehelsky, Jeffrey, Nochur, Sara, Walsh, Edward, Meyers, Rachel, Gollob, Jared and Vaishnaw, Akshay (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proceedings of the National Academy of Sciences, 107, (19), pp. 8800-8805. (doi:10.1073/pnas.0912186107).

More information

Published date: 11 May 2010
Organisations: Infection Inflammation & Immunity

Identifiers

Local EPrints ID: 153393
URI: http://eprints.soton.ac.uk/id/eprint/153393
ISSN: 0027-8424
PURE UUID: c50b1a2e-a771-4c33-99d2-a444ae8844e0

Catalogue record

Date deposited: 19 May 2010 15:44
Last modified: 18 Jul 2017 12:51

Export record

Altmetrics

Contributors

Author: John DeVincenzo
Author: Robert Lambkin-Williams
Author: Jeffrey Cehelsky
Author: Sara Nochur
Author: Edward Walsh
Author: Rachel Meyers
Author: Jared Gollob
Author: Akshay Vaishnaw

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×